Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091299 · ClinicalTrials.gov registry record · Phase 1
Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00091299 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 24 participants.
The verdict
NCT00091299, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Vatalanib may stop the growth of tumor cells by stopping blood flow to the tumor. Warfarin may be effective in preventing the formation of blood clots in patients who are undergoing treatment for advanced solid tumors. PURPOSE: This phase I trial is studying how well giving warfarin together with vatalanib works in treating patients with advanced solid tumors.
Interventions
- DRUG warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091299
The ClinicalTrials.gov registry entry for NCT00091299 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which warfarin is the first listed.
NCT00091299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091299 about?
NCT00091299 is a clinical study titled "Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors". RATIONALE: Vatalanib may stop the growth of tumor cells by stopping blood flow to the tumor. Warfarin may be effective in preventing the formation of blood clots in patients who are undergoing treatment for advanced solid tumors. PURPOSE: This phase I trial is studying how well giving warfarin toge...
What is the current status of trial NCT00091299?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00091299?
The interventions under investigation include: warfarin (DRUG).
Who is sponsoring clinical trial NCT00091299?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.